Anteris Technologies Global Corp. — Capital/Financing Update 2014

Jan 2, 2014

==> picture [226 x 82] intentionally omitted <==

ADMEDUS Ltd ABN 35 088 221 078

REGISTERED OFFICE: Level 1, 197 Adelaide Terrace Perth Western Australia 6000

PO Box 6879 East Perth Western Australia 6892

ASX ANNOUNCEMENT

T +61 (0)8 9266 0100 F +61 (0)8 9266 0199 E info.au@admedus.com

www.admedus.com

ADMEDUS COMPLETES ACQUISITION OF MANUFACTURING FACILITY

• Provides established infrastructure for CardioCel[®] production

• Provides experienced production team

• Accelerates scale up manufacturing of CardioCel[®] for global markets

Brisbane, Australia, 3rd January 2014

Admedus (ASX: AHZ) today announced the transaction to acquire an established manufacturing site from Genzyme Australia to facilitate scaled-up production of its lead regenerative tissue product CardioCel[®] has now been completed. The transaction was completed on the 31[st] of December, 2013 in accordance to the share purchase agreement.

The site is based in Malaga Western Australia and will provide fully operational infrastructure that will enable the company to service the global market for CardioCel[® ] a breakthrough new treatment for the repair and reconstruction of congenital heart defects.

It will also provide additional facilities to support the development and commercial manufacture of additional regenerative tissue products currently in the Admedus pipeline that utilise its platform ADAPT[®] tissue engineering process.

Admedus received CE mark for CardioCel[® ] in August 2013 and anticipates approval of CardioCel[®] in the US in 2014.

For more information, please contact:

Dr Julian Chick, Chief Operating Officer Admedus Limited Tel: +61 3 9620 5454

Media: Haley Price Buchan Consulting +61 39866 4722 hprice@buchanwe.com.au

MELBOURNE: BRISBANE: Suite 1307 Level 1, Highpoint Plaza 530 Little Collins Street 240 Waterworks Road Melbourne Victoria 3000 Ashgrove Queensland 4060

PERTH: Level 1 197 Adelaide Terrace Perth Western Australia 6000

==> picture [170 x 63] intentionally omitted <==

About Admedus Limited

Admedus (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Allied also has a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programs target disease with significant global potential such as Herpes and Human Papillomavirus.

Further information on the Company can be found on www.admedus.com

Admedus Regen

Admedus Regen started as a research program in 2001 focusing on tissue engineering and regenerative medicine based around the proprietary ADAPT[®] Tissue Engineering Process. The lead program, CardioCel[®] is approved in Europe and is being used in Australia under the Authorised Prescriber Scheme. CardioCel[®] is a cardiovascular scaffold used to repair paediatric and adult heart deformities. These deformities range from routine “hole in the heart” operations to major vessel outflow tract repairs. The CardioCel[®] scaffold may also be used to repair leaking heart valves in paediatric and adult patients. CardioCel[®] has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration ***** , suggesting that CardioCel[®] facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.

The division is based on the patented ADAPT[®] Tissue Engineering Process as a platform technology to produce implantable tissue scaffolds for use in various soft tissue repair applications and for the production of replacement tissue heart valves. The ADAPT[®] technology is used to process xenograft tissues to produce unique implantable tissue scaffolds that are compatible with the human body. The technology has a number of advantages over current tissue treatment processes on the market, most notably the reduction of calcification post implantation and has the potential to replace many of the products that surgeons currently use for soft tissue repair.

***** Körbling&Estrov, 2003. Adult Stem Cells for Tissue Repair — A New Therapeutic Concept? NEJM Volume 349:570-582, August 7, 2003, Number 6